News

Here’s a closer look at what the presidential candidates vow to do if elected to the Oval Office.

Spending on brand name drugs spiked 16.2% in 2015 and 98.2% since 2011, according to a new report from pharmacy benefit manager (PBM) Express Scripts. Plus, a third of branded products experienced price increases greater than 20% in 2015, according to Express Scripts’ annual Drug Trend Report.

The court will consider whether an “accommodation” allowing nonprofit religiously-affiliated organizations to opt out of the ACA requirement that insurance plans include contraception coverage is consistent with the Religious Freedom Restoration Act (RFRA).

Ensuring the appropriate internal investment, addressing key friction points, and taking several steps to increase the likelihood of long-term success is key.

PBM Express Scripts shares findings from its new Drug Trend Report.

An Affordable Care Act payment model is showing that chronically ill patients can be better taken care of in their own homes while bringing down the long-term cost of care.

The Managed Healthcare Executive Editorial Advisory Board says these skills are critical to be a successful healthcare executive today. Do you have what it takes?

During the keynote session at the Advanced Payment Models in Healthcare Conference 2016, PwC experts shared how MACRA legislation will affect reimbursement.

New Health Care Cost Institute analysis examines the value that can be derived from providing cost and quality information for non-emergency healthcare services.

The Centers for Disease Control and Prevention (CDC) issued new voluntary guidelines this week for prescribing opioid medications for chronic pain, excluding cancer, palliative, and end-of-life care.

We asked industry insiders to detail and analyze each component of Trump’s healthcare plan.

Captives can serve as focal points for the captive owners’ collective efforts to promote safer healthcare environments and improved patient outcomes.

US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.

Agency hits 30% value-based target goal 11 months ahead of schedule.

Surprising way a group of surveyed physicians are saying what they think is the best way to control costs.

Effective teams transform patient and caregiver experience by building trust and meeting goals. Here are five ways how.

FDA has approved expanded indication for the use of fulvestrant (Faslodex, AstraZeneca) in combination with another therapy in the treatment of metastatic breast cancer.

While FDA just approved the first generic version of sildenafil citrate (Viagra, Pfizer), the new product won’t be on the market until late 2017.

The 2016 Alternative Payment Models in Healthcare Conference 2016 is shedding light on which healthcare payment and delivery changes are evolving into large-scale, long-lasting solutions.

Learning to use mobile health or mhealth is a critical advantage to providing the highest return on investment for plans and providers.

The use of insulin management software in hospital emergency departments can decrease hospital admissions for diabetic ketoacidosis (DKA) by 45%, according to a new study.

While insurance companies and employers are deploying more pricing tools, healthcare providers are in a unique position to lead the price transparency revolution.

FDA has approved Odefsey (Gilead Sciences, Inc.) for the treatment of HIV-1 infection in certain patients. Here are the top 7 facts to know about Odefsey.

Health insurance plans will soon receive ratings based on how many doctors and hospitals they include in their networks.

While FDA recently approved ibrutinib (Imbruvica, Janssen Biotech, Inc. and Pharmacyclics LLC) to treat patients with chronic lymphocytic leukemia (CLL), United Kingdom’s National Institute of Health and Care Excellence (NICE) will not yet recommend the medication.

New data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin). Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk

Prior authorizations are here to stay. Are yours working against you? Find out.